about
Oral acyclovir suppression and neurodevelopment after neonatal herpesAntiretroviral prophylaxis for HIV prevention in heterosexual men and womenPrevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionHIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencingTransmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, MozambiqueEfficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineGenetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis.HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral ActivityImproved detection of rare HIV-1 variants using 454 pyrosequencing.Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150.A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women.Associations between genital tract infections, genital tract inflammation, and cervical cytobrush HIV-1 DNA in US versus Kenyan womenAn increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cellsHuman immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time.Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.Nevirapine-Resistant HIV-1 DNA in Breast Milk After Single-Dose Nevirapine With or Without Zidovudine for Prevention of Mother-to-Child TransmissionSimultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay.Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.Quantification of mitochondrial toxicity in HIV-infected individuals by quantitative PCR compared to flow cytometry.Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs.Comment on "The origins of sexually transmitted HIV among men who have sex with men".Antiretroviral treatment for HIV-infected infants exposed to nevirapine.Cross-contamination during processing of dried blood spots used for rapid diagnosis of HIV-1 infection of infants is rare and avoidable.Yet Another Reason to Treat HIV Infection
P50
Q24615077-12A9FEAB-2189-4B77-831C-21997AFD505FQ28270788-3F0080BF-AEA4-4B72-B327-E553B1DE8E7CQ28478459-851CCC5E-FCEC-44AE-A926-99CCD3E6359CQ28541918-62CC0D29-1CCF-4840-9FF6-76161B010903Q33798045-16D86D2B-35BE-497B-9FED-930FD6947BEAQ33798282-B54A46BE-9E64-47A5-98D4-62D567567D13Q33827080-35DC139B-89CE-46C4-8516-2E56030B8282Q33899918-C6A2471E-05FD-4E3E-82DF-5C76E618816EQ34048188-8017D361-19FF-4F02-9A38-88AC9160245AQ34071112-770C6B16-363C-4FC1-81AF-D8F0668BB2BAQ34178242-0233C684-FBB6-47E4-B96D-A637B1A4E204Q34329209-EC44AF05-8B42-4DB5-8C8E-2383ABE2477CQ34508433-190BC87B-2F32-4DF2-A4C5-DCCE92501B15Q34572571-2DEC2A28-FDE6-4A6B-B745-C194E56E94E4Q34785742-770F743C-5BEE-4943-A695-57478E58B5B7Q35009489-F637C450-9A15-49BB-B8C8-1DF1BFA4F6F5Q35032733-2DC4F37E-41CF-4F14-8821-D3511D5E9471Q35388475-541905E5-AD54-41EC-A2D1-F9DDAC33BCCEQ35583120-A79B0144-FCA7-4233-990B-91EC6BADE4B7Q35632898-BAEAAA89-C8CB-4455-82BA-567E44AAE524Q35862295-0285E278-55D2-424C-9E23-BBB2FB289280Q36102538-04D4CC8C-CC4A-43A3-801D-EE0E644C1EB3Q36154049-3D3964CC-4632-4205-8B02-EC6C9D2E2775Q36509620-37EC6E6B-B3A2-4971-A8F9-AEC0E826FF16Q36545289-DAACBFE1-E38D-4A25-B7CE-7174237D40F7Q36559821-924ECE4D-A72B-44F9-8A3D-80D7594BB001Q36702615-4C0DC111-8D68-47BC-BB4C-7D8EBD5EB197Q36795929-1E06BFDA-1BD1-4645-923A-DC14514289E2Q36851107-0FB456A9-0EE9-4793-A0F3-7BD1B1BC65DEQ37003038-DEC9D0E7-CB8D-4EAF-A645-45935057B44AQ37473017-8A65C41A-51DB-461A-902B-D2F4370180EEQ37663941-F63EB896-CDA5-43FD-A3DF-40EBA5FC4ACCQ37668877-96B8FCE6-921B-44C7-837A-3094D3EDD3D7Q42538205-7313DED2-2306-48DA-9D5E-651C5F8F630DQ42778954-BE2B73C8-09C8-46F0-A272-31E18FE90E98Q42924945-8085674E-71C4-4D6D-8324-AC479A14CBBDQ57999222-E05C35E0-3FB8-464F-B2A7-368A7294CCDA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lisa M Frenkel
@ast
Lisa M Frenkel
@en
Lisa M Frenkel
@es
Lisa M Frenkel
@nl
Lisa M Frenkel
@sl
type
label
Lisa M Frenkel
@ast
Lisa M Frenkel
@en
Lisa M Frenkel
@es
Lisa M Frenkel
@nl
Lisa M Frenkel
@sl
prefLabel
Lisa M Frenkel
@ast
Lisa M Frenkel
@en
Lisa M Frenkel
@es
Lisa M Frenkel
@nl
Lisa M Frenkel
@sl
P106
P21
P31
P496
0000-0001-9566-8959